GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Arcturus Therapeutics
Arcturus Therapeutics is a biotech company specializing in the development of mRNA vaccines and drugs. Its stock price is highly volatile and depends on the results of clinical trials. The chart tells the story of hopes for the next generation of mRNA drugs.
Share prices of companies in the market segment - Specialized pharma
Arcturus Therapeutics is a biopharmaceutical company focused on developing mRNA drugs and vaccines for infectious and rare diseases. We classify it in the Specialty Pharmaceuticals sector. The chart below shows how investors view the prospects of this cutting-edge field of medicine.
Broad Market Index - GURU.Markets
Arcturus Therapeutics is a biotech company specializing in the development of mRNA vaccines and therapeutics. As an innovator in this field, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it to Arcturus shares to assess the outlook for the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ARCT - Daily change in the company's share price Arcturus Therapeutics
Shares of Arcturus, a biotech company, exhibit high volatility, as measured by change_co. This reflects sensitivity to the results of clinical trials of its mRNA vaccines. This metric is important for biotech sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Arcturus Therapeutics Holdings Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ARCT's performance, which focuses on mRNA technologies, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Arcturus is a biopharmaceutical company specializing in mRNA therapeutics. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Arcturus's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Arcturus Therapeutics
Arcturus Therapeutics' year-over-year performance is a story of developing mRNA vaccines and next-generation therapeutics. Its market capitalization over the past 12 months depends entirely on the results of clinical trials. Success in trials can lead to multibillion-dollar contracts, while failure could wipe out years of work and investment.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Arcturus Therapeutics Holdings Inc. is a biotech company developing vaccines and mRNA-based therapeutics. Its stock price reflects both the potential of its scientific platform and the high risks associated with clinical trials, typical of this volatile biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Arcturus is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its mRNA platform trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Arcturus Therapeutics
Arcturus, a biopharmaceutical company, depends on its mRNA platform for growth. Monthly fluctuations on the chart reflect news about the clinical trials of its vaccines and therapeutics, the success of which determines its ability to compete with other players in this cutting-edge field.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Arcturus Therapeutics is a biotechnology company specializing in the development of mRNA vaccines and therapeutics for the treatment of infectious and rare diseases. The chart below shows the overall dynamics of the biotech sector, reflecting the high interest in mRNA technologies following their success during the pandemic.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies working with mRNA technologies can exhibit extreme volatility unrelated to the market. The chart below shows the overall sentiment. Is Arcturus Therapeutics moving in sync with it, or is news about its developments creating a completely independent story for the stock?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Arcturus Therapeutics
Arcturus Therapeutics, a biotech company developing mRNA vaccines and drugs, is experiencing high volatility. Its weekly stock price is a direct response to clinical trial data and pandemic news.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Arcturus operates in the volatile mRNA technology sector, where investor sentiment creates broad ripples. Any significant success or failure in the industry (such as Moderna or BioNTech) impacts everyone's risk appetite. The chart will show whether ARCT is following the general flow of biotech speculation or whether its news is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Arcturus Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how ARCT shares can live a life of their own, separate from the broader market.
Market capitalization of the company, segment and market as a whole
ARCT - Market capitalization of the company Arcturus Therapeutics
Arcturus Therapeutics' market capitalization is a story about the cutting edge of RNA medicine. The company is developing mRNA vaccines and therapeutics. Its price chart is a roller coaster, reflecting news about clinical trials and its competition with giants like Moderna and Pfizer. It's a bet on a technological platform of the future.
ARCT - Share of the company's market capitalization Arcturus Therapeutics within the market segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in RNA medicine, including the development of mRNA vaccines and therapeutics. Its share of its segment's market capitalization reflects the potential of its technology platform. The chart below shows the volatility of its valuation, particularly since the COVID-19 pandemic.
Market capitalization of the market segment - Specialized pharma
Arcturus Therapeutics develops mRNA vaccines and therapeutics. The chart below shows the market capitalization of the pharmaceutical sector. Following the success of its COVID-19 vaccines, this market has attracted significant attention, and Arcturus is one of its key innovators.
Market capitalization of all companies included in a broad market index - GURU.Markets
Arcturus Therapeutics is a biotechnology company specializing in the development of mRNA vaccines and drugs. The company's market capitalization reflects the potential of its technology platform, especially following the success of mRNA vaccines against COVID-19. Its stake in the pharmaceutical industry is a bet that mRNA will become the basis for the creation of many new vaccines and therapeutics.
Book value capitalization of the company, segment and market as a whole
ARCT - Book value capitalization of the company Arcturus Therapeutics
Arcturus Therapeutics' book value is a scientific platform for mRNA medicine. It consists of patents for its proprietary mRNA delivery technology (LUNAR®) and self-amplifying mRNA (STARR™), as well as cash for clinical trials. The chart below shows how the company uses its capital to develop next-generation vaccines and therapeutics.
ARCT - Share of the company's book capitalization Arcturus Therapeutics within the market segment - Specialized pharma
Arcturus Therapeutics develops mRNA vaccines using its own laboratories and partner manufacturing facilities. The S_BCap_Seg chart shows its share of the physical infrastructure of the innovative pharmaceutical sector.
Market segment balance sheet capitalization - Specialized pharma
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Arcturus, a company developing mRNA therapeutics, has a more streamlined model. But to produce its complex drugs, it is building its own facilities, becoming more capital-intensive.
Book value of all companies included in the broad market index - GURU.Markets
Arcturus Therapeutics is a biotech company specializing in mRNA drugs and vaccines. Its assets aren't massive factories, but rather a cutting-edge scientific platform and RNA delivery technologies. The chart below shows the financial clout behind this developer of "programmable" drugs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Arcturus Therapeutics
Arcturus's balance sheet is its mRNA scientific platform. The market evaluates not its current value, but its potential to create the next generation of vaccines and drugs that will be more effective than existing ones. The chart will show the premium investors are paying for this "bet" on scientific progress.
Market to book capitalization ratio in a market segment - Specialized pharma
Arcturus Therapeutics Holdings is a biotech company specializing in the development of mRNA drugs and vaccines. Its value lies in its technology platform. This chart shows how the market valuation, based on the potential of this cutting-edge technology, exceeds its book value by a multiple.
Market to book capitalization ratio for the market as a whole
Arcturus Therapeutics is a biotech company specializing in the development of mRNA drugs and vaccines. Its core value lies in its scientific platform and intellectual property. The chart shows how investors assess the potential of its technology to create new treatments, placing a bet on future scientific breakthroughs rather than current assets.
Debts of the company, segment and market as a whole
ARCT - Company debts Arcturus Therapeutics
Arcturus Therapeutics, a biotech company specializing in mRNA technologies, uses raised capital to fund its clinical programs. This chart shows how the company spends its funds on vaccine and therapeutic drug development, a long-term and risky process that requires ongoing funding.
Market segment debts - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in the development of mRNA vaccines and therapeutics. This technology requires significant investment in research and clinical trials. This chart shows how the company's debt policy reflects its capital needs to fund its scientific platform and compete with other players in this cutting-edge field.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Arcturus Therapeutics
Arcturus Therapeutics is a biotech company specializing in RNA therapeutics. This is a cutting-edge field that requires significant investment in research. This chart illustrates how heavily the company relies on external funding, including debt, to advance its promising but risky programs.
Market segment debt to market segment book capitalization - Specialized pharma
Arcturus Therapeutics, a biotech company specializing in the development of mRNA vaccines and therapeutics, compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company finances its cutting-edge scientific platform while competing with giants like Moderna and BioNTech.
Debt to book value of all companies in the market
Arcturus Therapeutics is a biotech company developing mRNA vaccines and therapeutics. This cutting-edge technology requires significant investment in research and clinical trials. This chart of total market debt provides insight into the availability of capital, which is vital for funding Arcturus's breakthrough but risky developments.
P/E of the company, segment and market as a whole
P/E - Arcturus Therapeutics
This figure for Arcturus Therapeutics, a biotech company developing mRNA vaccines and therapeutics, reflects the valuation of its scientific platform. Profitability may not be possible. The high figure indicates investors' confidence in the potential of its technology to create a new generation of drugs and vaccines, especially following the success of mRNA during the pandemic.
P/E of the market segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in the development of mRNA-based vaccines and therapeutics. This chart illustrates the average valuation in the specialty pharmaceuticals sector, where investors are betting on the potential of mRNA technology to treat a wide range of diseases.
P/E of the market as a whole
Arcturus Therapeutics is a biotech company specializing in the development of mRNA vaccines and therapeutics. Its platform gained prominence during the pandemic. This chart shows the overall sentiment in the biotech sector. Comparisons with it help clarify whether Arcturus is being valued based on the potential of its mRNA technologies to treat other diseases or whether its valuation follows broader trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Arcturus Therapeutics
This chart for Arcturus Therapeutics, a biotech developing mRNA vaccines and drugs, reflects market expectations for its clinical programs. It demonstrates investor confidence in the potential of its platform to develop new vaccines and therapeutics, which shapes its future valuation.
%20P%2FE%20Arcturus%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Arcturus-Therapeutics&v=1772680427493 "Chart of the company's future (projected) P/E Arcturus Therapeutics")
Future (projected) P/E of the market segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in the development of mRNA vaccines and drugs. This chart shows average expectations for the biotech sector. ARCT's position may indicate how investors view its unique mRNA delivery technology and the potential of its developments in infectious diseases and rare diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772680427507 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Arcturus Therapeutics develops mRNA vaccines and drugs. This is at the forefront of biotechnology. The company's valuation depends on scientific breakthroughs. The overall market optimism, evident in this chart, facilitates the funding needed for expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772680427541 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Arcturus Therapeutics
Arcturus Therapeutics is a biotechnology company specializing in the development of messenger RNA (mRNA) for vaccines and therapeutics. This chart reflects innovation in medicine. Periods of loss are due to high research costs, while a potential surge in profit depends on the success of its mRNA platform and the approval of new products.
Profit of companies in the market segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in the development of mRNA vaccines and drugs. Profitability in the specialty pharmaceutical sector, as this chart shows, has seen a huge boost during the pandemic. For ARCT, the goal is to apply its technology platform to the development of new vaccines and therapeutics beyond COVID-19.
Overall market profit
Arcturus Therapeutics, a biopharmaceutical company working on mRNA therapeutics, is at the forefront of science. Its value is determined by the potential of its technology platform and success in clinical trials. The overall market environment, reflected in this chart, is important primarily for attracting funding for expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Arcturus Therapeutics
Arcturus Therapeutics develops mRNA-based vaccines and therapeutics. This chart reflects analysts' forecasts for future revenue, which are dependent on the success of its clinical programs, including next-generation vaccines. This chart assesses the scientific potential of its self-amplifying mRNA platform.
%20profit%20of%20the%20company%20Arcturus%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Arcturus-Therapeutics&v=1772680427675 "Graph of future (projected) profit of the company Arcturus Therapeutics")
Future (predicted) profit of companies in the market segment - Specialized pharma
Arcturus Therapeutics is a biotechnology company specializing in the development of messenger RNA (mRNA) for vaccines and therapeutics. The company's technology became known during the pandemic. This chart shows the revenue forecast for the pharmaceutical sector, reflecting expectations for the development and commercialization of advanced mRNA technologies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772680427717 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Arcturus Therapeutics is a biopharmaceutical company developing mRNA vaccines and drugs. Its value is determined by the success of its clinical programs, not the economic cycle. However, the overall profit outlook is important for the investment climate. During periods of optimism, investors are more willing to fund risky biotech projects, making it easier for Arcturus to raise capital.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772680427740 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Arcturus Therapeutics
Arcturus Therapeutics is a biotech company specializing in the development of RNA vaccines and therapeutics. Its revenue depends on partnerships and research grants. The chart shows how the market values its scientific platform, especially after the pandemic, when interest in RNA technologies has surged.
P/S market segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in the development of mRNA vaccines and therapeutics. This chart shows the average revenue valuation in the biotech industry. It helps us understand how highly investors value its mRNA platform and its potential for developing new drugs compared to the industry average.
P/S of the market as a whole
Arcturus Therapeutics is a biotech company specializing in the development of RNA vaccines and therapeutics. Its mRNA technology gained widespread attention during the pandemic. A chart of average market revenue estimates serves as a backdrop to the huge premium investors are paying for the potential of this cutting-edge scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Arcturus Therapeutics
Arcturus Therapeutics is a biotech company specializing in RNA medicine. The chart shows how the market values its innovative platform. The company's value is determined by projected future revenues from its vaccines and therapeutics in development, which is a bet on the success of its science.
%20P%2FS%20Arcturus%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Arcturus-Therapeutics&v=1772680427930 "The graph of the company's future (projected) P/S Arcturus Therapeutics")
Future (projected) P/S of the market segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in RNA medicine, including the development of vaccines and therapeutics. The data in the chart reflects average market expectations for future sales in the specialty pharmaceuticals sector. This allows us to assess how highly investors value Arcturus's RNA platform and its potential compared to competitors.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772680427959 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Arcturus Therapeutics is a biotech company working on mRNA therapeutics. Its value is tied to the potential of its scientific platform. This graph of overall revenue expectations is irrelevant. Investors are focused entirely on clinical trial results. The success of a single drug can change the company's fortunes, regardless of the economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772680427983 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Arcturus Therapeutics
Arcturus Therapeutics is a biotech company specializing in the development of messenger RNA (mRNA) for vaccines and therapeutics. The revenue shown in this chart likely comes from partnerships with major pharmaceutical companies. These payments are critical to funding its innovative research.
Sales of companies in the market segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in developing messenger RNA (mRNA) for disease treatment and vaccine development. Their technology enables the body to naturally produce therapeutic proteins. This chart shows the sector's total revenue, reflecting the enormous potential and growing investment in mRNA technologies following the success of the COVID-19 vaccines.
Overall market sales
Arcturus Therapeutics is a biopharmaceutical company specializing in the development of RNA drugs. This chart shows the state of the economy, but for ARCT, scientific progress is paramount. Its platform enables the creation of next-generation vaccines and therapeutics. The company's success depends on clinical trial results, not GDP.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Arcturus Therapeutics
Arcturus Therapeutics is a biotechnology company specializing in the development of RNA vaccines and therapeutics. Its future depends on the success of clinical trials and the approval of its innovative products. This chart reflects market expectations regarding the potential of its RNA platform for treating various diseases.
%20sales%20of%20the%20company%20Arcturus%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Arcturus-Therapeutics&v=1772680428025 "Schedule of future (projected) sales of the company Arcturus Therapeutics")
Future (projected) sales of companies in the market segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in the development of RNA vaccines and therapeutics. Its self-replicating RNA technology can provide a stronger and longer-lasting immune response. The chart shows forecasts for the specialty pharmaceutical sector. Arcturus's success depends on the breakthrough of its RNA platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772680428046 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Arcturus Therapeutics is a biotech company specializing in the development of mRNA vaccines and drugs. Its success depends on the results of clinical trials and its ability to attract funding. This schedule, reflecting overall economic confidence, influences the investment climate in the biotech sector, which affects the company's ability to finance its expensive developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772680428098 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Arcturus Therapeutics
Arcturus Therapeutics is a biotechnology company specializing in the development of messenger RNA (mRNA) for vaccines and therapeutics. The company has high research costs. This chart illustrates the financial side of cutting-edge science, where today's investments can lead to the creation of breakthrough and profitable drugs.
Market segment marginality - Specialized pharma
Arcturus Therapeutics is a biotechnology company specializing in the development of mRNA drugs and vaccines. This chart shows the average profitability in the pharmaceutical industry. Its unique self-replicating RNA technology gives the company the potential to create highly effective drugs and achieve profitability significantly higher than the industry average.
Market marginality as a whole
Arcturus Therapeutics is a biotech company developing mRNA vaccines and therapeutics. Its financial health is determined by clinical research expenditures and the potential of its technology platform. This total return chart vividly illustrates the contrast between risky but potentially breakthrough biotech startups and consistently profitable corporations.
Employees in the company, segment and market as a whole
Number of employees in the company Arcturus Therapeutics
Arcturus Therapeutics is a biotech company working with mRNA technologies. Its team consists of highly specialized scientists. This chart shows the company's investment in the human capital necessary to develop and advance its innovative vaccines and therapeutics through clinical trials.
Share of the company's employees Arcturus Therapeutics within the market segment - Specialized pharma
Arcturus Therapeutics is a biotechnology company specializing in the development of mRNA vaccines and therapeutics. mRNA technology requires cutting-edge scientific expertise. This chart shows the percentage of leading scientists in this complex and competitive field that Arcturus attracts. It reflects its scientific prowess and potential for creating next-generation drugs.
Number of employees in the market segment - Specialized pharma
Arcturus Therapeutics Holdings Inc. is a biotechnology company specializing in the development of mRNA vaccines and therapeutics. The growth of its scientific team, visible in this chart, is directly related to progress in clinical trials. This increase in staff indicates active work on several programs, including next-generation vaccines.
Number of employees in the market as a whole
Arcturus Therapeutics Holdings is a biotech company developing mRNA therapies. Its success depends on scientific innovation and clinical trial results, not on the economic cycles shown in this chart. The company operates at the forefront of medicine, where breakthroughs can create enormous value regardless of the labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Arcturus Therapeutics (ARCT)
Arcturus Therapeutics is a biotech company developing mRNA therapies. Its market capitalization is a bet on its scientific platform. This chart shows an extremely high valuation of intellectual capital. The company's entire value is attributed to its small team of scientists, resulting in a huge per-employee ratio.
%20of%20the%20company%20Arcturus%20Therapeutics%20(ARCT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Arcturus-Therapeutics-ARCT&v=1772680428384 "Chart of market capitalization per employee (in thousands of dollars) of the company Arcturus Therapeutics (ARCT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in RNA medicine. Its entire value lies in its cutting-edge scientific platform and the potential of its vaccines and therapies. This chart shows how investors value the company's intellectual capital per scientist working on future drugs.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772680428399 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Arcturus Therapeutics is a biotechnology company specializing in the development of mRNA vaccines and therapeutics. The chart illustrates the valuation of this cutting-edge scientific platform. The very high market capitalization per employee reflects the enormous potential of their technology, especially following the success of mRNA vaccines during the pandemic.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772680428423 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Arcturus Therapeutics (ARCT)
Arcturus Therapeutics is a biotech company specializing in mRNA therapeutics (like Moderna/BioNTech). This is cutting-edge science. This graph likely shows a negative value. It measures how much capital is "burned" per scientist working on the next generation of vaccines and drugs. This is the cost of innovation in mRNA.
%20Chart%20Arcturus%20Therapeutics%20(ARCT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Arcturus-Therapeutics-ARCT&v=1772680428459 "Company Profit Per Employee (in thousands of dollars) Chart Arcturus Therapeutics (ARCT)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Arcturus (ARCT) is an R&D biotech (mRNA technologies). This chart shows the benchmark for "Specialty Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772680428463 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Arcturus Therapeutics (ARCT) is a biotechnology company specializing in mRNA technologies for vaccines and therapeutics. The company is in active R&D and clinical trials. This graph will likely show a loss per employee, as all resources are invested in research and development rather than sales.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772680428489 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Arcturus Therapeutics (ARCT)
Arcturus Therapeutics develops mRNA vaccines and drugs. For a biotech company, this chart reflects progress in monetizing its platform. Increased revenue per employee typically reflects advance payments from major pharmaceutical partners, validating the value of its cutting-edge scientific research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Arcturus-Therapeutics-ARCT&v=1772680428512 "Sales chart per company employee Arcturus Therapeutics (ARCT)")
Sales per employee in the market segment - Specialized pharma
Arcturus (ARCT) is a biotech company specializing in mRNA technologies (vaccines, therapeutics). They were active during the pandemic. They are an R&D platform. This chart shows their current phase. Without a stable commercial product (like Moderna), their revenue per employee will be low and dependent on partner fees (from CSL) and grants.
Sales per employee for the market as a whole
Arcturus Therapeutics is a biotech company specializing in RNA (mRNA) therapeutics. This is cutting-edge science. During the R&D phase, this metric reflects investment in the future. It will only begin to grow sharply if their complex therapeutic approaches are approved and commercialized, demonstrating the leverage of their intellectual property.
Short shares by company, segment and market as a whole
Shares shorted by company Arcturus Therapeutics (ARCT)
Arcturus (ARCT) is a biotech company specializing in mRNA technologies. Unlike Moderna/Pfizer, their focus is on self-amplifying mRNA (for vaccines) and drugs for rare liver diseases. This metric measures skepticism. "Bears" doubt the advantage of their mRNA platform or the success of their clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Arcturus-Therapeutics-ARCT&v=1772680428640 "Short Shares Chart for the Company Arcturus Therapeutics (ARCT)")
Shares shorted by market segment - Specialized pharma
Arcturus Therapeutics (ARCT) is a biotech company specializing in mRNA therapeutics (like Moderna), but with a focus on "self-amplifying" mRNA (STARR). This chart shows bets against the entire biotech sector. The rising bets against the industry reflect investor skepticism about the success of this technology following the pandemic hype.
Shares shorted by the overall market
Arcturus Therapeutics is a clinical-stage biotech company working with mRNA. Its value represents the hope for future drugs. When this market fear indicator rises, investors are unwilling to hold out hope. They sell off unprofitable, speculative biotechs en masse, like ARCT, which need constant funding.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Arcturus Therapeutics (ARCT)
Arcturus Therapeutics is a biotech company working with mRNA. The stock is highly volatile and dependent on R&D. This chart can surge above 70 on positive trial data. Oversold levels (<30) are often associated with research setbacks, funding concerns, or a general downturn in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Arcturus-Therapeutics-ARCT&v=1772680428696 "RSI 14 indicator chart for the company's stock Arcturus Therapeutics (ARCT)")
RSI 14 Market Segment - Specialized pharma
Arcturus Therapeutics is a biotech company specializing in mRNA-based drug development. Its focus includes COVID-19 vaccines and treatments for rare liver diseases. This chart measures the collective momentum of the mRNA biotech sector. It clearly shows when the entire niche is overheated by expectations or oversold by setbacks.
RSI 14 for the overall market
Arcturus Therapeutics (ARCT) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ARCT (Arcturus Therapeutics)
Arcturus Therapeutics (ARCT) is a biotech company specializing in RNA technologies. It is developing mRNA vaccines (including for COVID-19) and therapeutics using its self-amplifying RNA (STARR) platform. This chart shows the average analyst forecast, reflecting their assessment of the potential of this mRNA platform compared to competitors.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ARCT-Arcturus-Therapeutics&v=1772680428796 "A chart showing analyst consensus forecasts for the expected stock price. ARCT (Arcturus Therapeutics)")
The difference between the consensus estimate and the actual stock price ARCT (Arcturus Therapeutics)
Arcturus Therapeutics is a biotech company specializing in the development of mRNA vaccines and therapeutics. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, demonstrating whether experts believe in their mRNA platform in a post-COVID world.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ARCT-Arcturus-Therapeutics&v=1772680428847 "A chart showing the difference between the consensus forecast and the actual stock price. ARCT (Arcturus Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Arcturus Therapeutics (ARCT) is a biotech company specializing in mRNA therapeutics. Unlike vaccines, their platform can self-amplify (sa-mRNA). This chart shows general expectations for the specialty pharma sector. It reflects whether experts believe in the next generation of mRNA technologies.
Analysts' consensus forecast for the overall market share price
Arcturus (ARCT) is a clinical-stage biotech developing self-amplifying mRNA therapy. This is a risky R&D story. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with revolutionary potential. Pessimism = risk aversion, and capital for R&D dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Arcturus Therapeutics
Arcturus is a biotech company working at the forefront of RNA medicine (like Moderna/BioNTech). Their signature technology is self-amplifying mRNA (STARR), which promises stronger and longer-lasting effects at lower doses. This chart is an assessment of their R&D platform. It reflects the market's confidence in their technology for COVID vaccines and treatments for rare diseases.
AKIMA Market Segment Index - Specialized pharma
Arcturus (ARCT) is a clinical-stage biotech and a pioneer in mRNA technologies (as BioNTech); the company is developing a unique self-amplifying mRNA platform (STARR) for vaccines and therapeutics. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (STARR) R&D platform (ARCT) differentiate it from the average pharma company?
The AKIM Index for the overall market
Arcturus Therapeutics is a biotech company developing mRNA vaccines and drugs (for example, for cystic fibrosis) using a unique delivery system (LUNAR). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative platform compares to overall economic trends in biotech.
